Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
iN Therapeutics logo — 의학 및 약학 연구개발업

iN Therapeutics

의학 및 약학 연구개발업

Founded 2020 Korea South Korea South 8 employees Series B Total: $40.00B Biotechnology, Health and Wellness +1

General Information

Company Name iN Therapeutics
Founded Year 2020
Location Korea South Korea South
Employees 8
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with iN Therapeutics. To contact iN Therapeutics, visit intherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does iN Therapeutics compare?

A PDF of iN Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting iN Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About iN Therapeutics

is a biotech startup based in Korea South, established in 2020. It is a spin-off from the renowned pharmaceutical company, Daewoong Pharmaceuticals, and focuses on medical and pharmaceutical research and development. The company has developed a cutting-edge drug discovery platform for ion channel, Nav1.7 non-opioid analgesic, as well as treatments for hearing loss and neurological diseases. With a decade of experience, iN Therapeutics possesses the world’s premier ion channel evaluation platform and development knowledge, making it a promising player in targeting various CNS (Central Nervous System) diseases. Recently, iN Therapeutics secured a significant KRW26.00B Series B investment on 07 February 2022 from a noteworthy group of investors including Aju IB Investment, DAYLI Partners, E&Investment, InterVest, STIC, Timefolio Asset Management, Shinhan Capital, Kiwoom Investment, and Yuanta Investment. This injection of funds is a testament to the company’s potential and the confidence investors have in its innovative approach to drug development and disease treatment. Overall, iN Therapeutics’ strong industry connections, innovative approach, and strategic partnerships position it as a promising player in the biotechnology and pharmaceutical sectors, with potential for significant growth and impact in the medical field.

Business keywords: Biotech, Pharmaceuticals, Drug discovery, Ion channel, Non-opioid analgesic, Hearing loss, Neurological diseases, CNS diseases, Biomedical research, Medical technology, Therapeutics, Research and development, Spin-off, New drug development, Biopharmaceuticals

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B KRW26.00B 9
Aju IB Investment DAYLI Partners E&Investment
Aju IB Investment, DAYLI Partners +7
07 Feb 2022
Series A KRW14.00B 1
Aju IB Investment
Aju IB Investment
25 Feb 2021

iN Therapeutics Alternatives & Competitors

View All Alternatives
iN Therapeutics vs
Hoba Therapeutics
Hoba Therapeutics Denmark

Developing Restorative Treatments for Chronic Neuropathic Pain and Hearing Loss

Series A
15 employees
Biotechnology, Health Care
iN Therapeutics vs
AGY Therapeutics
AGY Therapeutics

Pioneering breakthrough treatments for central nervous system diseases through innovative gene disco...

Series C
Biopharma, Biotechnology
iN Therapeutics vs
Autifony Therapeutics
Autifony Therapeutics

Autifony are dedicated to developing new medicines to treat rare genetic CNS disorders

Venture round
37 employees
Biotechnology, Health and Wellness
Compare iN Therapeutics vs Autifony Therapeutics
Also compare with: iN Therapeutics vs NMD Pharma A/S NMD Pharma A/S View all alternatives

FAQ About iN Therapeutics

의학 및 약학 연구개발업
iN Therapeutics was founded in 2020.
iN Therapeutics is headquartered in Korea South.
iN Therapeutics operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on Biotech, Pharmaceuticals, Drug discovery and Ion channel.
iN Therapeutics has approximately 8 employees.
iN Therapeutics has completed 2 funding rounds, raising a total of $40.00B. The latest funding stage is Series B.
Top alternatives and competitors to iN Therapeutics include Hoba Therapeutics, AGY Therapeutics, Autifony Therapeutics, Kineta (Reverse Merger With Yumanity Therapeutics), NMD Pharma A/S. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
iN Therapeutics and Hoba Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for iN Therapeutics, https://bouncewatch.com/company/in-therapeutics, updated 11 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout